SLC5A2 and heart failure: Trials like DAPA-HF, EMPEROR-Reduced, EMPEROR Preserved, and DELIVER have demonstrated the ability of SGLT2 inhibitors to reduce the risk of heart failure hospitalization and cardiovascular death in HFrEF, HFpEF, and HFmrEF (McMurray et al., 2019; Packer et al., 2020; Anker et al., 2021; Solomon et al., 2022).